title: Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
abstract: Adrenocortical cancers are relatively rare endocrine tumors that usually present when hormonally active or after they have become large and metastasis has occurred. Consequently, the 5-year survival rate is 20% to 35%. Surgical removal remains the only form of therapy proven to prolong survival. Mitotane is the most accepted form of chemotherapy. For the approximately 20% to 25% of patients whose tumors respond to mitotane, survival is prolonged.
authors.affiliation: Departments of Surgery and Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Demeure
authors.forename: L B
authors.initials: LB
authors.lastname: Somberg
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D000315:Adrenalectomy; D018268:Adrenocortical Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology* / Q000556:secondary / Q000601:surgery; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D006801:Humans; D008939:Mitotane / Q000627:therapeutic use; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal; D008939:Mitotane